UY38595A - Métodos para el tratamiento de enfermedades relacionadas con tnfa - Google Patents
Métodos para el tratamiento de enfermedades relacionadas con tnfaInfo
- Publication number
- UY38595A UY38595A UY0001038595A UY38595A UY38595A UY 38595 A UY38595 A UY 38595A UY 0001038595 A UY0001038595 A UY 0001038595A UY 38595 A UY38595 A UY 38595A UY 38595 A UY38595 A UY 38595A
- Authority
- UY
- Uruguay
- Prior art keywords
- methods
- tnf
- tnfa
- treatment
- related diseases
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para el tratamiento de una enfermedad relacionada con TNF-a mediante la administración subcutánea de un anticuerpo que se une a TNF-a (anticuerpo anti-TNF-a) o fragmento de unión a antígeno del mismo. En comparación con la inyección intravenosa, el método de tratamiento, la composición, el kit o el uso de acuerdo con la presente invención, ofrece la ventaja de mejorar la satisfacción del paciente, al mejorar su comodidad y calidad de vida, es decir, al reducir el tiempo requerido para la administración y disminuir la estancia del paciente en el hospital.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190023769 | 2019-02-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY38595A true UY38595A (es) | 2020-09-30 |
Family
ID=72239651
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001038595A UY38595A (es) | 2019-02-28 | 2020-02-27 | Métodos para el tratamiento de enfermedades relacionadas con tnfa |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220153828A1 (es) |
JP (1) | JP2022521996A (es) |
KR (1) | KR20200105439A (es) |
AR (1) | AR118191A1 (es) |
BR (1) | BR112021016913A2 (es) |
CA (1) | CA3130921A1 (es) |
TW (1) | TW202045137A (es) |
UY (1) | UY38595A (es) |
WO (1) | WO2020175954A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA45562B1 (fr) | 2016-06-30 | 2024-05-31 | Celltrion Inc | Préparation pharmaceutique liquide stable |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2868614A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
MX361242B (es) * | 2011-03-30 | 2018-11-30 | Ablynx Nv | Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos. |
KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
-
2020
- 2020-02-26 AR ARP200100519A patent/AR118191A1/es unknown
- 2020-02-27 TW TW109106508A patent/TW202045137A/zh unknown
- 2020-02-27 UY UY0001038595A patent/UY38595A/es unknown
- 2020-02-28 WO PCT/KR2020/002886 patent/WO2020175954A1/ko active Application Filing
- 2020-02-28 KR KR1020200024817A patent/KR20200105439A/ko unknown
- 2020-02-28 BR BR112021016913A patent/BR112021016913A2/pt unknown
- 2020-02-28 CA CA3130921A patent/CA3130921A1/en active Pending
- 2020-02-28 JP JP2021550084A patent/JP2022521996A/ja active Pending
- 2020-02-28 US US17/430,628 patent/US20220153828A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3130921A1 (en) | 2020-09-03 |
BR112021016913A2 (pt) | 2021-11-03 |
KR20200105439A (ko) | 2020-09-07 |
WO2020175954A1 (ko) | 2020-09-03 |
AR118191A1 (es) | 2021-09-22 |
US20220153828A1 (en) | 2022-05-19 |
JP2022521996A (ja) | 2022-04-13 |
TW202045137A (zh) | 2020-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003888A (es) | Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos. | |
CO2018007582A2 (es) | Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1 | |
BR112021009856A8 (pt) | Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l | |
CO6150193A2 (es) | Terapia tumoral con anticuerpo anti-vegf | |
AR110751A1 (es) | Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con proteínas de unión al receptor del péptido inhibidor gástrico (gipr) | |
ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
CO6270370A2 (es) | Inhibicion de angiogenesis mediante antagonistas o anticuerpos bv8 | |
EA201890182A1 (ru) | Терапевтическое средство для лечения синдрома гунтера и способ его лечения | |
CL2011002416A1 (es) | Uso de un anticuerpo anti-il 17a y/o il-17f o fragmento que une antígeno del mismo que sirve en la preparación de un medicamento para el tratamiento de un trastorno de resistencia a insulina en un mamifero; kit. | |
CO2023002206A2 (es) | Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas trem2 | |
UY38595A (es) | Métodos para el tratamiento de enfermedades relacionadas con tnfa | |
CL2022001984A1 (es) | Composiciones métodos para aumentar, mejorar transducción vectores de terapia génica y para eliminar, reducir inmunoglobulinas | |
PE20200013A1 (es) | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 | |
BR112019022912A2 (pt) | Métodos e composições para tratar doenças oculares alérgicas | |
AR117735A1 (es) | ANTICUERPOS MONOCLONALES QUE SE UNEN ESPECÍFICAMENTE A LA REGIÓN b DE LA FAMILIA TRBV-9 DEL RECEPTOR DE CÉLULAS T HUMANO, Y LOS MÉTODOS PARA SU USO | |
BR112023022264A2 (pt) | Esteroide c21-n-pirazolil 19-nor c3,3-dissubstituído e métodos de uso do mesmo | |
DOP2020000049A (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa | |
MX2022016087A (es) | Anticuerpos que unen el tgf-alfa y la epirregulina para su uso en el tratamiento del dolor. | |
BR112022009798A2 (pt) | Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer | |
EA202290027A1 (ru) | Способы и композиции для улучшения результатов лечения пациентов с раком | |
MX2021011711A (es) | Canagliflozina para el tratamiento de pacientes diabeticos con enfermedad renal cronica. | |
CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas | |
EA202190504A1 (ru) | Способы лечения псориаза | |
AR112535A1 (es) | MÉTODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNFa | |
BR112021019478A2 (pt) | Primeira, segunda e terceira proteínas de fusão compreendendo anticorpos anti-mesotelina, anti-cd3 e anti-egfr, anticorpos biespecífico e triespecífico, composição farmacêutica que compreende os mesmos e usos das ditas proteínas e anticorpos, bem como da dita composição farmacêutica para tratar câncer |